Company profile
Lipella Pharmaceuticals Inc.
OTC: LIPO · Healthcare · Biotechnology
#929 of 1,418 Healthcare companies by revenue65th-percentile growth
EA Score
——FH —DQ 19GM —SS 13
v0.1 · 25/100 weight · pillars only
↑ balance-sheet leverage, 3-yr revenue growth · ↓ Piotroski F, market scale
Methodology →Revenue TTM
$173.7k
Rev growth YoY (TTM)
-61.4%
Net income (FY)
-$5.0M
Employees
7
as of 2026-08-26
Market cap
$1.8k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$536.4k$536.4k2024
Net income-$5.0M-$5.0M2024
Operating income-$5.1M-$5.1M2024
Total assets$2.7M$2.7M2024
Liabilities$754.4k$754.4k2024
Equity$1.9M$1.9M2024
Revenue trend
FY2022 – FY2024 · USD
FY22
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2022
By product
Grant Revenues100%
By geography
Not disclosed.
The read
What is Lipella Pharmaceuticals Inc.’s revenue?
Lipella Pharmaceuticals Inc. booked $536.4k in FY2024 revenue, growing 19% year over year — faster than most Healthcare companies we track, at a -935.2% net margin.
Peers · Healthcare
Trevena, Inc.——Solana Company49DCardax, Inc.——Sibannac, Inc.——Medivolve Inc.——DiaMedica Therapeutics Inc.35DNeighbors
Allegheny →Key facts
CEOJonathan Kaufman
SectorHealthcare
IndustryBiotechnology
HeadquartersPittsburgh, PA
ExchangeOTC: LIPO
Employees7
IPO date2022-12-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.